D1 vs D2 Lymphadenectomy in Gastric Cancer

Prognostic Implications of D1 vs D2 Lymphadenectomy in Gastric Cancer: a Propensity Score Matched Analysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05253430

Enrollment

357

Registered

2022-02-23

Start date

1990-04-30

Completion date

2021-02-28

Last updated

2022-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

gastric cancer, lymphadenectomy, outcomes

Brief summary

This study is a retrospective study with a propensity score-matched analysis in order to balance differences between patients with D1 and D2 lymphadenectomy for gastric cancer.The main aim is to analyse differences in the postoperative and oncological outcomes of patients with gastric cancer (GC) who underwent D1 and D2 gastrectomy.

Detailed description

In this propensity score-matched analysis of 128 patients, D2 lymphadenectomy improved long-term outcomes compared with D1 in patients with curative intent surgery for gastric cancer except for the group of patients older than 75 years and with early tumors.

Interventions

PROCEDURELymphadenectomy type

D1 vs D2 lymph node dissection

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients diagnosed with GC stage I-III who underwent a curative gastrectomy +/- perioperative chemotherapy

Exclusion criteria

* patients with adenocarcinoma Siewert type I/II, palliative surgery, R1/R2 resections and pathological stage (pStage) IV.

Design outcomes

Primary

Measure	Time frame	Description
Disease-free survival	percentage of patients without disease recurrence alive at 3 and 5 years after surgery	Disease-free survival (DFS) was defined as the time from gastric surgery to the date of recurrence (locoregional, peritoneal recurrence and/or distant metastases).

Secondary

Measure	Time frame	Description
Overall survival	percentage of patients alive at 3 and 5 years after surgery	Overall survival (OS) was defined as the time from the date of surgery to the date of death from any cause
Postoperative morbidity	from the surgery up to 90 days after the surgery	Surgical complications were defined as any deviation from the normal postoperative course within 90 days after surgery, both during the hospital stay or after discharge.
Postoperative mortality	from the surgery up to 90 days after the surgery	Mortality through post-operative follow-up

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026